<SEC-DOCUMENT>0001193125-25-030794.txt : 20250220
<SEC-HEADER>0001193125-25-030794.hdr.sgml : 20250220
<ACCEPTANCE-DATETIME>20250220165321
ACCESSION NUMBER:		0001193125-25-030794
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250220
DATE AS OF CHANGE:		20250220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276774
		FILM NUMBER:		25646305

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d812844d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-276774 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
December&nbsp;2, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>475,555 American Depositary Shares representing 47,555,560 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g812844g0220144541335.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December&nbsp;2, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on February 20, 2025 (the &#147;February 20, 2025 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have attached
the February 20, 2025 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements
the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction
with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On February 20, 2025, the last reported sale price of
the ADSs on Nasdaq was $0.8790 per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk
Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently
filed reports and, if any, in any applicable prospectus supplement. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is February 20, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of February, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February 20, 2025, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press release titled &#147;Kazia Therapeutics and
the Hebrew University of Jerusalem Receive Michael J Fox Foundation Research Grant to Evaluate the Therapeutic Potential of Paxalisib for the Treatment of Parkinson&#146;s Disease&#148;. A copy of this release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit
99.1, except for the quote of Dr.&nbsp;John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company&#146;s registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-276091</FONT> and <FONT STYLE="white-space:nowrap">333-281937).</FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST
</U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated February 20, 2025</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited </B>(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 20 February 2025</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g812808g0220201824652.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20&nbsp;February 2025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of
Paxalisib as a Treatment for Parkinson&#146;s Disease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, February&nbsp;20, 2025 &#150; Kazia Therapeutics Limited (NASDAQ: KZIA)
(&#147;Kazia&#148; or &#147;the Company&#148;), an oncology-focused drug development company, today announced a research grant awarded from The Michael J. Fox Foundation for Parkinson&#146;s Research (MJFF) to fund research between The Hebrew
University of Jerusalem (Hebrew University) and Kazia to explore the therapeutic potential of paxalisib as a treatment for Parkinson&#146;s disease (PD). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The grant will fund collaborative preclinical studies at Professor Ronit Sharon&#146;s lab (Hebrew University) aimed at establishing an operational link
between a specific pathway in the pathophysiology of PD and paxalisib. The research will assess the impact of paxalisib on mouse survival, motor and <FONT STYLE="white-space:nowrap">non-motor</FONT> performances, as well as specific biochemical,
pathological and molecular disease biomarkers that will be determined in brains of treated mice. Paxalisib is a unique, blood-brain barrier-penetrating inhibitor for class IA phosphatidylinositol <FONT STYLE="white-space:nowrap">3-kinase</FONT>
(PI3K), and data generated from this research is expected to provide valuable insights into its potential activity for the treatment of PD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are
pleased to enter into this exciting collaboration with Dr.&nbsp;Ronit Sharon and The Hebrew University of Jerusalem, whose groundbreaking research has led to important discoveries related to neuronal degeneration in Parkinson&#146;s disease and
related synucleinopathies,&#148; said Dr.&nbsp;John Friend, Kazia&#146;s CEO. &#147;Overexpression of human <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-synuclein A53T (<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-SynA53T) in dopamine neurons is
an underlying hallmark and contributor of Parkinson&#146;s disease. As a brain-penetrant PI3K inhibitor, we believe paxalisib may have the potential to address the underlying pathophysiology of PD by inhibiting AKT phosphorylation reaction of <FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-SynA53T, and the preclinical models we intend to explore will help answer this critical question.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The main
goal of this research is to delve into the therapeutic potential of paxalisib, a drug that can enter the brain, and inhibit class IA phosphatidylinositol <FONT STYLE="white-space:nowrap">3-kinase</FONT> (PI3K). The preliminary findings from
Professor Ronit&#146;s lab obtained in PD brains and supported by <FONT STYLE="white-space:nowrap">in-vivo</FONT> data in a mouse model for PD, collectively emphasize the role of the canonical PI3K/AKT/mTORC pathway in the pathogenesis of PD. The
preclinical research from this grant builds upon earlier data obtained in PD brains, <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-SynA53T tg mouse brains and cell models for PD, which collectively emphasize a distinct role for <FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-Syn in hyper-activating the PI3K/AKT/mTORC2 pathway to facilitate <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-Syn&#146;s activity in neuronal lipid metabolism. More information can be found at
https://www.michaeljfox.org/grant/exploring-paxalisib-novel-therapeutic-parkinsons-disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor and Media Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alex Star, Managing Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LifeSci Advisors LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-201-786-8795.</FONT></FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astarr@lifesciadvisors.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g812808g0220201824652.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an
investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this
disease. A completed Phase 2/3 study in glioblastoma <FONT STYLE="white-space:nowrap">(GBM-Agile)</FONT> was reported in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval.
Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for
glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in
combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in
June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and
has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For more information, please visit
www.kaziatherapeutics.com or follow us on X @KaziaTx. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148;
&#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials,
Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801, potential results of research between Hebrew University and Kazia regarding the therapeutic potential of paxalisib for the treatment of Parkinson&#146;s
disease, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies, and the potential market opportunity for paxalisib. Such statements are based on
Kazia&#146;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the
forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks
and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes
no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements,
which apply only as of the date of this announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorized for release by Dr John Friend, CEO. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g812808g0220201824652.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g812808g0220201824652.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U *@# 2(  A$! Q$!_\0
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MD!SUQQ@UWBG*@^HI--*XTTW86BD9@BEF("@9)-<CX1\<0^)]4U2S553[/)F
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(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g812844g0220144541335.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g812844g0220144541335.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W;: !@=*I
M:IJ/]F6#S^7N.0%!]3ZT_4Y9HM,GD@ ,BK\N/UK&T":YU-+B'4%:6' QO'>M
M*=-<O,]ET.6K6:G[..[6CZ(6'4+G6M&NO)C\NY3"_*>#]#VXIOAZRU&WMKI9
M=T:NN(U8\[N>:M76HZ3X?*6[D1B0Y"J/PR:I>(?%+Z1=VZ00B5)(]^X]QZ"E
M+$1BG&*TN:4L#4J.,Y7YM?),9H-CJ=MJ$LEPK+'M)DR<ASZBK6G^(FNM6^RM
M %1B50@\\>M6[OQ'I]D;>.[<H\RA@N,[0?6IFL+6".6\M84^T,A96 ZYJU6C
M-OF6K_ R>&J4(IINVKU_0T_J*?VKD_#E[J%S?RQW)=HPN3O['VKJ_6LYQY'8
MUHU55AS)6'44T=*\<7QYKY\?_P!EFX06G]H_9PNP9V;\?RI)-HU;L['LU%<5
MXZ\8IX7T_P JW*OJ,H_=J>=@_O&J7P\U3Q+KL4NHZK.IL2NV)=@!<_WOI1RN
MUQ<RO8]"HIJYVC/I1SNQ2*'4E>:'X@'_ (68-,\P?V7_ ,>V?^FO][\^*]+'
M2FTT)-,7M24=J\Y^('B#7]$OK*/1U<I)&Q?;%NYS^E)*[!NQZ-1FO )OB'XP
MML>?(8MWW?,AVYKT#X<:QKFOVUU?ZK,K6^X1P (!EA]X_P A5N#2N)23._HQ
M31Z5Y'XO\;:[H_C233;*=4MU\K"E ?O8SS4Q38W*QZ_144#%H$8]2H)J6D,*
M0UA^*=:C\/Z!=:@S .B$1 ]W/2L?X>^)Y/$6@9NY-]];-LF_V@>0?R_E3Y7:
MXKJ]CM**%.112&<?J>JZC!K/DQ(?+# *N.&%:FM:F-'TIKM8=S9 "CID^M4;
M'7A>ZPL#VZA6)"-CD8IGB;74TQX[-[59EF7<P;ICI^=:57RQ2:MH88*'/5<K
M\R;V]"M!96OC*RCO[E'BFB)B.T\,,UTK:=:21Q)) CB$ )N&<4FG) NGPFWB
M$<;*&"@=,UQNH:U>3WTFR5D16(514X>@ZM[,UQF-]C;>UW9'0:KX:L]7NDGF
M)#(-IQW JIIGB8SZ[_97V8K$I,:'N,<<UI^'+^6_T[=,<R1G:3ZUBZYK5OHF
MNIY5BC32*&>3')S6,X.G)^IT4JOMX)-7TT\C0U^[NK$0BT!029W.JUJZ5/-<
M:;!+<KME9>14.J7XL]+%UY0<'&%8=,U'H6IMJELSR1A6C;''0UT-.4-MCSHI
M0K<KENMC:':OFC4;S^SOB#>7VW?]GU%Y0OKA\U]+BOG QI/\47AD4-&^K,K*
M>X,F**?4WGT+.A6<_C[QNS:A< *Q,L@SSM'\*U[]:VT-I:QV]NBQQ1J%15'
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0M%)10,6BDHH 6BDHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
